Surrozen (SRZN) Retained Earnings (2020 - 2026)
Surrozen (SRZN) recorded quarterly Retained Earnings of -$654.8 million in Q1 2026, down 24.18% quarter-over-quarter from -$527.3 million in Q4 2025, and down 109.72% on a YoY basis from $6.7 billion in Q1 2025.
Surrozen (SRZN) Retained Earnings (2020 - 2026) Analysis & Trends
Surrozen's Retained Earnings history runs 7 years deep, the most recent figure standing at -$654.8 million for Q1 2026.
- In Q1 2026, Retained Earnings fell 109.72% year-over-year to -$654.8 million; the TTM figure through Mar 2026 stood at -$654.8 million (down 109.72% YoY), while the FY2025 annual figure was -$527.3 million, down 84.84% from the prior year.
- Retained Earnings was -$654.8 million for Q1 2026 at Surrozen, down from -$527.3 million in the prior quarter.
- In the past five years, Retained Earnings ranged from a high of $5000.0 in Q2 2023 to a low of -$654.8 million in Q1 2026.
- Historically, Retained Earnings has averaged -$239.8 million across 5 years, with a median of -$230.5 million in 2024.
- The sharpest annual moves came in 2023 and 2024: Retained Earnings surged 100.0% in 2023, then slumped 25720100.0% in 2024.
- A 5-year view of Retained Earnings shows it stood at -$178.7 million in 2022, then declined by 24.09% to -$221.7 million in 2023, then decreased by 28.67% to -$285.3 million in 2024, then slumped by 84.84% to -$527.3 million in 2025, then slipped by 24.18% to -$654.8 million in 2026.
- The last three Retained Earnings figures came in at -$654.8 million (Q1 2026), -$527.3 million (Q4 2025), and -$344.1 million (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Retained Earnings (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 788,338.31 Bn | 788,338.28 Bn | - | -153.89 Mn |
| 2 | Belite Bio | 56,560.00 Bn | 56,560.00 Bn | - | - |
| 3 | Quantum Biopharma | 17,329.30 Bn | 17,329.30 Bn | - | -211.85 Mn |
| 4 | Legend Biotech | 3,341.00 Bn | 3,340.71 Bn | 242.10 Mn | 1.00 Bn |
| 5 | Akari Therapeutics | 1,727.91 Bn | 1,727.91 Bn | - | -279.00 Mn |
| 6 | Evaxion A | 1,536.68 Bn | 1,536.67 Bn | - | 130.89 Mn |
| 7 | Psyence Biomedical | 238.34 Bn | 238.33 Bn | - | -1.88 |
| 8 | Vertex Pharmaceuticals | 113.42 Bn | 106.17 Bn | 2.59 Bn | 14.59 Bn |
| 9 | Abivax | 95.45 Bn | 95.45 Bn | - | -838.07 Mn |
| 10 | Surrozen | 239,016.67 | -106.67 Mn | - | -654.80 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -654.80 Mn |
| Dec 31, 2025 | -527.29 Mn |
| Sep 30, 2025 | -344.10 Mn |
| Jun 30, 2025 | -272.48 Mn |
| Mar 31, 2025 | -312.23 Mn |
| Dec 31, 2024 | -285.26 Mn |
| Sep 30, 2024 | -257.20 Mn |
| Jun 30, 2024 | -255.80 Mn |
| Mar 31, 2024 | -230.53 Mn |
| Dec 31, 2023 | -221.70 Mn |
| Sep 30, 2023 | 1,000.00 |
| Jun 30, 2023 | 5,000.00 |
| Mar 31, 2023 | -193.00 Mn |
| Dec 31, 2022 | -178.65 Mn |
| Sep 30, 2022 | -177.88 Mn |
| Jun 30, 2022 | -164.50 Mn |
| Mar 31, 2022 | -429,000.00 |
| Dec 31, 2021 | -119,000.00 |
| Sep 30, 2021 | -16,000.00 |
| Jun 30, 2021 | -5.94 Mn |